KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $12.9 million.

  • Royalty Pharma's Other Operating Expenses rose 10566.82% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.6 million, marking a year-over-year decrease of 11252.38%. This contributed to the annual value of $732.5 million for FY2024, which is 3064.36% up from last year.
  • Per Royalty Pharma's latest filing, its Other Operating Expenses stood at $12.9 million for Q3 2025, which was up 10566.82% from -$111.4 million recorded in Q2 2025.
  • Royalty Pharma's Other Operating Expenses' 5-year high stood at $924.7 million during Q4 2022, with a 5-year trough of -$238.0 million in Q2 2021.
  • Over the past 5 years, Royalty Pharma's median Other Operating Expenses value was $164.0 million (recorded in 2024), while the average stood at $161.5 million.
  • Over the last 5 years, Royalty Pharma's Other Operating Expenses had its largest YoY gain of 61304.83% in 2021, and its largest YoY loss of 54901.81% in 2021.
  • Over the past 5 years, Royalty Pharma's Other Operating Expenses (Quarter) stood at $272.3 million in 2021, then skyrocketed by 239.55% to $924.7 million in 2022, then tumbled by 108.27% to -$76.5 million in 2023, then skyrocketed by 314.39% to $164.0 million in 2024, then crashed by 92.14% to $12.9 million in 2025.
  • Its Other Operating Expenses was $12.9 million in Q3 2025, compared to -$111.4 million in Q2 2025 and -$127.1 million in Q1 2025.